I can't see why Shire wouldn't want generic Humira unless they feel that with dozens of other companies involved the competitive landscape is unfavorable.
SHPG doesn't have any FoB programs, so they may decide that M923 falls outside their scope of interest.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”